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Abstract
Background—Prevalence estimates of anal high-risk human papillomavirus (HR-HPV) are 
needed in sub-Saharan Africa where HIV is endemic. This study evaluated anal HR-HPV in 
Nigeria among HIV-positive and HIV-negative men who have sex with men (MSM) for future 
immunization recommendations.
Methods—We conducted a cross-sectional study to compare the prevalence of anal HR-HPV 
infections between 64 HIV-negative and 90 HIV-positive MSM. Multivariate Poisson regression 
analyses were used to examine demographic and behavioral risk factors associated with any HR-
HPV infections.
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Results—The median age of the 154 participants was 25 years (interquartile range [IQR]: 22-28, 
range: 16-38) and the median age at initiation of anal sex with another man was 16 years (IQR: 
13-18, range: 7-29). The prevalence of anal HR-HPV was higher among HIV-positive than HIV-
negative MSM (91.1% vs. 40.6%, p<0.001). In the multivariate analysis, HIV infection (adjusted 
prevalence ratio [aPR]: 2.02, 95% CI: 1.49-2.72), ten years or more since anal sexual debut (aPR: 
1.26, 95% CI: 1.07-1.49), and concurrent relationships with men (aPR: 1.32, 95% CI: 1.04-1.67) 
were associated with increased anal HR-HPV prevalence.
Conclusions—Anal HR-HPV infection is high for young Nigerian MSM and rates are amplified 
in those co-infected with HIV. Providing universal coverage as well as catchup immunization for 
young MSM may be an effective anal cancer prevention strategy in Nigeria.
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Introduction
The rising incidence of anal cancer in the US is linked to the syndemic of HIV and 
coincident high risk human papillomavirus (HR-HPV) infection among men who have sex 
with men (MSM). Anal cancer risk is 80 times higher among HIV-infected MSM as 
compared to HIV-uninfected individuals, with the most oncogenic genotypes being HPV16 
followed by HPV18 and HPV33 [1-3]. Antiretroviral therapy (ART) has restored systemic 
immunity, but has done little to regress anal precancerous lesions [4, 5] or prevent an 
increase in anal cancer incidence in HIV-positive men [1, 6-7]. These unexpected trends in 
the era of ART highlight the complexity of HPV transformation and the need to prevent 
initial infection with effective HPV vaccines.
Most prevalence studies of anal HR-HPV in HIV-infected MSM have occurred in North 
America, Europe, Australia and Asia [8-14]. A meta-analysis of cross-sectional studies 
primarily from the United States estimated the pooled prevalence of any HPV was higher in 
HIV-positive as compared to HIV-negative MSM (93% vs. 64%) [15]. A similar pattern 
existed for HR-HPV (74% vs. 37%) [15]. More data are needed to describe the burden of 
anal HR-HPV in HIV-endemic regions such as sub-Saharan Africa for adequate anal cancer 
control program development. This is especially important since with longer survival times 
expected for HIV-infected populations in sub-Saharan Africa, anal cancer trends are likely 
to parallel and possibly surpass the current trends seen in the United States where the 
incidence rates among men increased between 2000 to 2009 [6]. The 9-valent HPV vaccine 
which includes protection against five additional HR-HPV types (31, 33, 45, 52, and 58) 
was recently approved in December 2014 by the U.S. Food and Drug Administration for 
males between the ages of 9 to 15 years [16]. The anticipated impact of the 9-valent HPV 
vaccine on anal HPV burden is difficult to estimate in an HIV endemic area such as Nigeria 
where the diversity of HR-HPV has not been characterized.
The objective of this study is thus to evaluate the prevalence of anal HR-HPV and associated 
demographic and behavioral risk factors in a cohort of young HIV-positive and HIV-
negative Nigerian MSM to better inform future vaccination recommendations.
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Study design and Population
We conducted a cross-sectional study at the Abuja site of the TRUST study that has been 
previously described [17]. In brief, the TRUST study has recruited Nigerian MSM through 
respondent-driven sampling (RDS) since March 2013. Eligibility criteria included: 1) a valid 
RDS coupon; 2) born male; 3) history of anal intercourse, insertive or receptive, with 
another man in the past 12 months; 3) age 16 years or older, with 16-17 year olds considered 
emancipated minors and exempt from parental consent; and 4) ability and willingness to 
provide written informed consent. At enrollment (visit 0), participants provided 
demographic, sexual behavior and clinical data through in person interviews by the trained 
staff using a standardized questionnaire. Two weeks after enrollment (visit 1), participants 
underwent HIV counseling and testing and received physical exams where anal swabs, urine 
and blood were collected for sexually transmitted infection (STI) diagnostics. Two anal 
swabs from the APTIMA swab kit were inserted by a doctor about 2cm into the anorectum, 
rotated, and placed in transport medium. Specimens were aliquoted and stored at minus 
80°C prior to testing. At the time of this analysis, participants who had completed HIV 
testing, had an anal swab sample at visit 1, and were among those recruited early in the 
TRUST study by their peers (wave 1-10 of network chains) were included in this study 
(n=165).
This study was conducted in collaboration with the Institute of Human Virology at the 
University of Maryland, the Institute of Human Virology Nigeria, Johns Hopkins 
University, the International Center for Advocacy on the Right to Health, and the U.S. 
Military HIV Research Program. The study was approved by the Federal Capital Territory 
Health Research Ethics Committee in Nigeria, the University of Maryland Baltimore 
Institutional Review Board (IRB), and the Walter Reed Army Institute of Research IRB.
Laboratory Procedures
Whole blood was tested for HIV using rapid test kits (Abbott Determine HIV-1/2, Chembio 
HIV-1/2 Stat Pak, and Trinity biotech Uni-Gold HIV test for discordant results) as outlined 
by the parallel testing algorithm for high-risk individuals in Nigeria [18]. If a participant was 
HIV-positive, HIV RNA viral loads were quantified using the COBAS TaqMan HIV-1 Test 
(Roche Molecular Diagnostics, CA) and CD4 counts were estimated using the Partec 
CyFlow Counter. Anal swabs were tested for Neisseria gonorrhoeae and Chlamydia 
trachomatis using the Aptima Combo 2 CT/NG Assay (Hologic, CA). Participants testing 
positive for HIV and/or STIs were offered ART regardless of CD4 counts and antibiotic 
therapies. A physical examination of the anorectum was conducted for detection of warts. 
Depending on the size of the warts, the participants were either treated with liquid nitrogen 
immediately or referred to the Nigerian Defense Headquarters Medical Center for surgical 
excision.
For HPV analyses, DNA was extracted from 250 μl of Aptima Specimen Transport medium 
using the QIAamp MinElute Media Kit (Qiagen, CA). DNA was resuspended in 100μl of 
Buffer AVE. A 10μl aliquot of the purified DNA was amplified using the PGMY 09/11 L1 
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consensus primer system [19] which co-ampifes 37 HPV genotypes and a human beta-
globin internal control target. Both high and low-risk HPV genotypes were detected using 
the Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, CA)[20]. HR-HPV 
included 13 type specific infections: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 
[21]. HPV52 was considered positive if there was no cross reaction with HPV33, HPV35 or 
HPV58. HPV52 status in men with HPV33, HPV35, or HPV58 is therefore unknown. The 
remaining 24 genotypes detected were considered low-risk. Quality control samples were 
included during DNA extraction, PCR amplification and genotype detection steps. Among 
the 165 samples tested, 8 were excluded from the analysis because they did not have 
sufficient cellular material to detect HPV genotypes. The final analytic sample size was 157.
Statistical Analyses
The primary outcome variable for all analyses was a binary categorization of having any 
anal HR-HPV type specific infections. A person was considered positive if one or more of 
the 13 HR-HPVs was detected. Prevalence of any HPV, vaccine preventable-types in the 9-
valent vaccine (HPV6, 11, 16, 18, 31, 33, 45, 52, 58), HR-HPV not in the 9-valent vaccine 
(HPV35, 39, 51, 56, 59, 68), and individual high-risk type specific infections between HIV-
positive and HIV-negative were also assessed. The main independent variable was HIV 
infection status. Demographic characteristics (i.e., age, education, marital status, religion, 
and sexual orientation), behavioral factors [i.e., age at anal sexual debut, years since anal 
sexual debut, number of men had receptive sex in past year, sexual positioning (insertive 
only or any receptive), condom use with receptive sex, and any female sexual partners], and 
concurrent sexually transmitted infections (i.e., rectal gonorrhea, rectal chlamydia, and anal 
warts) were also evaluated as independent risk factors for HR-HPV. Variables related to 
immunodeficiency (CD4 counts, viral loads, WHO stage and ART status) were summarized 
for the HIV-positive MSM. The baseline demographics of HIV-positive and HIV-negative 
MSM were compared using Pearson's chi-square tests for categorical variables and 
Wilcoxon rank sum tests for continuous variables. Univariate and multivariate Poisson 
regression models with robust error variance were used to estimate prevalence ratios (PR) 
and 95% confidence intervals (CI) for the association between independent risk factors and 
anal HR-HPV infection. Size of personal network, as a form of weighting, was included in 
all multivariate models to account for the respondent driven sampling design. A directed 
acyclic graph (DAG) was generated using DAGitty [22] to identify the minimal set of a 
priori confounders (sexual behavior, size of personal network and age) needed to adjust for 
the association between HIV infection and HR-HPV without introducing selection bias from 
over adjustment [23] (see Figure, Supplemental Digital Content 2, for DAG illustration). 
The final multivariate model adjusted for years since anal sexual debut, sexual positioning, 
concurrency, and size of personal network. Female partners was not included in the final 
model because it did not confound the main association (<10% change in estimated effect) 
and was significantly associated with concurrency. Age was not included in the model 
because it was positively correlated with years since sexual debut. Analyses were performed 
using Stata Statistical Software: Release 13 (College Station, TX: StataCorp LP).
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A total of 154 participants (64 HIV-negative and 90 HIV-positive) were included in the 
analytic sample size, after removing 3 subjects with any missing data on a priori 
confounders (years since sexual debut, sexual positioning or female partners). Participants 
missing data on descriptive covariates were retained in the analysis.
Overall, participants were young (median age=25 years; interquartile range [IQR]: 22-28, 
range: 16-38) and initiated anal sex at a young age (median age=16 years; IQR: 13-18, 
range: 7-29). Participants engaged in sexual activities both with men (median number of 
receptive sexual partners=3; IQR: 1-5) and women (median number of vaginal sexual 
partners=1; IQR:0-2).
Compared to HIV-negative men, HIV-positive men were older, had larger personal 
networks of MSM, engaged in more unprotected receptive sex, and were diagnosed with 
concurrent anal warts (Table 1). For HIV-positive MSM, less than half were receiving 
antiretroviral therapy (ART; n=39, 43%) at study entry, the median CD4+ cell count was 
320 cells/μl (IQR: 221-425), a third (n=29, 32%) had a viral load ≥ 100,000 copies/ml, and 
24% (n=22) had a WHO stage of 2 at enrollment.
The prevalence of any HPV, any HR-HPV, any of the 9 vaccine-preventable HPV strains 
(6/11/16/18/31/33/45/52/58), and any non-vaccine HR-HPV strain ((35/39/51/56/59/68) was 
higher in the HIV-positive MSM as compared to the HIV-negative MSM (Figure 1). 
Approximately 59% (53/90) of HIV-positive and 83% (53/64) of HIV-negative MSM did 
not have a prevalent HPV16 or HPV18 infection. HPV35 had the highest point prevalence 
(34.4%) among HIV-positive MSM, followed by HPV58 (27.8%), HPV51 (26.7%), HPV18 
(25.6%), HPV45 (25.6%) and HPV16 (23.3%) (see Figure, Supplemental Digital Content 1, 
for type-specific prevalence by HIV status). HPV16 had the highest point prevalence 
(12.5%) among HIV-negative MSM, followed by HPV51 (9.4%), HPV35 (7.8%), HPV58 
(7.8%), HPV52 (6.3%) and HPV31 (6.3%) (see Figure, Supplemental Digital Content 1, for 
type-specific prevalence by HIV status).
As shown in the unadjusted analysis in Table 2, risk factors for HR-HPV included HIV 
infection, longer duration since anal sexual debut, and larger personal networks of MSM. 
Younger age and having female sex partners were associated with a lower prevalence of 
HR-HPV. Initiation of anal sex before age 13, any receptive sex in the past year, and 
increasing numbers of anal receptive sex partners in the past year were positively associated 
with HR-HPV. For HIV-positive MSM, there was no difference in HR-HPV by category of 
CD4 counts (<200, 200-349, 350+, p=0.90), viral load (<100, 100-99,999, 100,000+, 
p=0.81), WHO stage (1 vs. 2, p=0.34), or self-report of ART at study entry (p=0.94).
As shown in the multivariate analysis in Table 3, HIV infection was significantly associated 
with a 2-fold increased prevalence of HR-HPV infection (Table 3). The proportion of MSM 
with anal HR-HPV was approximately 26% higher if they had ten or more years since 
sexual debut. Similarly, MSM in concurrent relationships strictly with men had an 
approximately 32% higher prevalence of anal HR-HPV, as compared to MSM with no 
Nowak et al. Page 5













concurrent relationships. Practicing any receptive sex was no longer significantly associated 
with anal HR-HPV.
Discussion
Our study of young Nigerian MSM demonstrated a high prevalence of anal HR-HPV during 
HIV infection. The most prevalent HR-HPV type specific infections that occurred in both 
the HIV-positive and HIV-negative MSM were HPV35, HPV58, HPV51 and HPV16, with 
HPV16 not being the dominant HR-HPV infection among the HIV-positive. Given the 
diversity of HR-HPV infection, most of the HR-HPV types would be prevented with the 9-
valent vaccine except HPV35 and HPV51. Interestingly, a large proportion of our 
participants were not currently HPV16 or 18 DNA positive, highlighting an opportunity to 
provide catch up immunization to prevent infection with the most oncogenic genotypes. In 
terms of risk factors, HIV infection was the strongest predictor for anal HR-HPV infection. 
In addition, more than ten years since anal sexual debut and concurrent relationships with 
men were independently associated with an increased prevalence of anal HR-HPV 
infections.
Our baseline prevalence of anal HR-HPV infection in those co-infected with HIV, was 
similar to the prevalence observed in Australia (94%) [12] and higher than those reported 
from North America (ranging from 56% to 80%) [7-9], Europe (ranging from 65% to 79%) 
[10-11], Asia (ranging from 58% to 61%) [13-14], and the summary prevalence of 74% 
(95% CI, 64-83) from a meta-analysis [15]. Although the Australian study had a similar 
prevalence, its study population significantly differed in their age composition and sexual 
risk behavior. The Australian study was comprised of much older men in their mid-forties 
with an initiation of sex over 20 years prior and more than a third reporting over 500 lifetime 
number of sex partners. In contrast, our study was comprised of much younger HIV-positive 
MSM (79% less than 30 years of age) with lower risk behavior. Sexual debut occurred 10 
years prior and their personal networks included a median of 35 men. Geographic 
distributions of HPV prevalence may explain the higher detectability of HR-HPV in our 
study as compared to the other studies. In a meta-analysis comparing the prevalence of 
cervical human papillomavirus among women with normal cytological findings, the 
prevalence of HPV was higher in Western Africa which includes Nigeria (19.6%) as 
compared to North America (4.7%) [24]. The higher prevalence may also be the result of 
underreporting of sexual risk behavior because our observed prevalence among the HIV-
negative MSM was the same as the prevalence reported from a geographically distinct 
region (Seattle, Washington). The Seattle study population had a similar age composition 
and exposure time since sexual debut with another man [25]. Other studies of HIV-negative 
MSM with differing age compositions and exposure times have estimated anal HR-HPV in 
the range of 27% to 73% [7, 9, 11-15, 26]. Additional studies of anal HPV are needed from 
young MSM in sub-Saharan Africa to confirm the breadth of diversity observed in our 
study.
Among HIV-positive MSM, HPV35 and 51 were among the most common and HPV16 
ranked 6th in prevalence. Other studies among Nigerian women documented HPV35 as one 
of the more prevalent high-risk type specific infections [27, 28]. One Nigerian study found 
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invasive cervical cancers were predominantly associated with HPV16 (68%) and 18 (10%) 
as compared to HPV35 (6%) [28], therefore HPV35 and possibly HPV51, even though 
highly prevalent, may not be as persistent or oncogenic as HPV16 and HPV18. Longitudinal 
studies are needed to better understand persistence of and progression of non-HPV16 or 18 
HR-HPVs in Nigeria to better understand their contribution to anal cancer risk.
Similar to other studies, HIV infection and markers of sexual behavior (ie. longer duration 
since sexual debut) were independent predictors of anal HR-HPV [7-8, 11-12, 25-26]. The 
prevalence of anal HR-HPV was higher among MSM who had concurrent relationships with 
men. Having female partners was initially protective in the univariate analysis. This finding 
is consistent with a study from China, where female partnerships were not associated with 
anal HR-HPV [29]. Female partners are potentially a surrogate marker of lower exposure to 
HPV from receptive sex. However, this risk is not mitigated for their female partners given 
the high prevalence of HIV and HR-HPV among the MSM. Additional studies are needed to 
to find effective interventions that increase uptake of cervical cancer screening among 
female partners of MSM, who may not be aware of their exposure risk. Other markers of 
sexual behavior, such as number of receptive partners and unprotected receptive sex, were 
positively associated with anal HR-HPV.
Our study had a few limitations. Data on lifetime number of sexual partners, one of the 
strongest sexual risk factors, was not collected in this cohort, but estimates of personal 
networks of MSM was available and potentially accounted for this risk factor in the analysis. 
Another strong risk factor for HPV is smoking, which was not collected in our cohort. If 
smoking behavior is differential by HIV status, then the independent estimates of HIV 
would move towards the null. Next, participants were asked to report their sexual behavior 
over the past 12 months potentially introducing recall bias in terms of their behavior with 
men, women and condom use. However, most of these variables were in the expected 
direction and the precision of these associations would have been strengthened with a larger 
sample size. Lastly, this was a cross sectional study that was not able to assess directionality 
between HIV and anal HR-HPV infections. Despite these limitations, estimates of anal HR-
HPV prevalence in Nigeria are not based on a convenient sample and may be generalizable 
to other young MSM with similar risk behaviors given that this sample achieved greater than 
8 waves of recruitment. There was no significant difference in the prevalence of anal HR-
HPV between waves 1-5 vs. waves 6-10 (data not shown), suggesting that equilibrium was 
reached [30]. Because the sampling design was accounted for in the analysis by adjusting for 
personal network size, inferences about the study population are generalizable to other 
comparable MSM populations in sub-Saharan Africa. Overall, these baseline estimates of 
anal HR-HPV are needed to inform follow-up analyses on incident and persistent infections.
In summary, our study documents a high burden of anal HR-HPV infection among young 
MSM from Nigeria, particularly those infected with HIV. HPV35, 58 and 51 were more 
common than 18, 45, and 16 among the HIV-positive MSM. The high proportion of MSM 
naïve to HPV16 and 18 offers an opportunity to provide catch up immunization to prevent 
anal cancer. Future studies are needed to assess anal HR-HPV persistence and progression to 
neoplasia given the breadth of types detected in this study to better understand the potential 
effectiveness of the 9-valent vaccine to reduce the burden of HPV-associated malignancies.
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Figure 1. Prevalence of any HPV, high-risk HPV, nonavalent vaccine types, and non-vaccine 
HR-HPV types in HIV+ and HIV- MSM (n=154 men)
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Table 1
Baseline Demographics of HIV-positive and HIV-negative MSM
Baseline Characteristics
HIV+ n=90 HIV- n=64
No. (%) No. (%) P*
Age (years) 0.11
 16-19 8 (8.9) 13 (20.3)
 20-29 63 (70.0) 41 (64.1)
 30-38 19 (21.1) 10 (15.6)
 Median [IQR] 26 [23-28] 24 [20-28] 0.03
Education 0.06
 ≤ Primary 9 (10.5) 2 (3.1)
 Secondary 43 (50.0) 43 (67.2)
 ≥Tertiary 34 (39.5) 19 (29.7)
Marital status 0.18
 Never married 73 (81.1) 57 (89.1)
 Ever married 17 (18.9) 7 (10.9)
Religion 0.36
 Christian/Protestant 71 (79.8) 47 (73.4)
 Muslim/Other 18 (20.2) 17 (26.6)
Sexual Orientation 0.82
 Bisexual 61 (68.5) 45 (70.3)
 Homosexual 28 (31.5) 19 (29.7)
Age of anal sexual debut (years) 0.33
 ≤12 31 (34.4) 15 (23.4)
 13-18 48 (53.3) 39 (60.9)
 19-27 11 (12.2) 10 (15.6)
 Median [IQR] 15 [12-18] 16 [15-20] 0.03
Number of years since first anal sex 0.01
 0-9 45 (50.0) 45 (70.3)
 10-26 45 (50.0) 19 (29.7)
 Median [IQR] 10 [6-15] 5 [3-11] <0.001
Size of personal network (No. of men) 0.14
 ≤10 23 (25.6) 23 (35.9)
 11-50 40 (44.4) 30 (46.9)
 ≥51 27 (30.0) 11 (17.2)
 Median [IQR] 35 [10-80] 16 [10-38] 0.02
No. of men had receptive sex in past year 0.10
 None 14 (15.9) 19 (30.7)
 1-6 57 (64.8) 33 (53.2)
 7+ 17 (19.3) 10 (16.1)
 Median [IQR] 3 [1-6] 3 [0-5] 0.21
Sexual positioning in past year 0.04
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Baseline Characteristics
HIV+ n=90 HIV- n=64
No. (%) No. (%) P*
 Insertive only 14 (15.6) 19 (29.7)
 Any receptive 76 (84.4) 45 (70.3)
Receptive sex and condom use in past year 0.02
 No receptive sex 12 (13.5) 19 (30.2)
 Always condoms 33 (37.1) 25 (39.7)
 Inconsistent condoms 44 (49.4) 19 (30.2)
Any female sexual partners in past year 0.54
 No 41 (45.6) 26 (40.6)
 Yes 49 (54.4) 37 (59.4)
Concurrency in past year 0.41
 None 22 (24.4) 14(21.9)
 Men only 42 (46.7) 25 (39.1)
 Both men and women 26 (28.9) 25 (39.1)
Rectal gonorrhea 0.93
 Neg 63 (74.1) 47 (73.4)
 Pos 22 (25.9) 17 (26.6)
Rectal chlamydia 0.87
 Neg 69 (86.3) 52 (85.3)
 Pos 11 (13.8) 9 (14.8)
Anal warts <0.01
 No 73 (82.0) 62 (96.9)
 Yes 16 (18.0) 2 (3.1)
Any HPV type <0.001
 No 1 (1.1) 22 (34.4)
 Yes 89 (98.9) 42 (65.6)
Any HR-HPV types† <0.001
 No 8 (8.9) 38 (59.4)
 Yes, a 9-valent type 21 (23.3) 12 (18.8)
 Yes, a non-vaccine type 61 (67.8) 14(21.9)
Note: No=number; IQR=interquartile range; Neg=negative; Pos=positive; HR-HPV=high-risk human papillomavirus; P=p-value
*
Pearson's chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables
†
9-valent HPV vaccine types [16/18/31/33/45/52/58] and non-vaccine types [35,39,51,56,59,68]
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Table 3
Multivariate Poisson regression analysis of characteristics and factors associated with 
high-risk HPV (HR-HPV) among MSM in Nigeria
Variable aPR (95% CI)
HIV
 Neg Ref.
 Pos 2.02 (1.49-2.72)
Years since first anal sex
 0-9 Ref.
 10-26 1.26 (1.07-1.49)
Sexual positioning†
 Insertive only Ref.
 Any receptive 1.26 (0.91-1.73)
Concurrency†
 None Ref.
 Men only 1.32 (1.04-1.67)
 Both men and women 1.00 (0.76-1.31)
Size of personal network (No. of MSM) ‡ 1.00 (1.00-1.00)
Note: HPV=human papillomavirus; MSM=men who have sex with men; aPR=adjusted prevalence ratio; CI=confidence intervals; Neg=negative; 
Pos=positive; No.=number; Ref.= reference category.
†
reported in past year
‡
continuous variable
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